Lantern Pharma's LP-184 Shows Promise in Pediatric Brain Cancer Treatment
TL;DR
Lantern Pharma's LP-184 shows promising results in improving survival rates for pediatric brain cancer, potentially revolutionizing treatment.
LP-184 by Lantern Pharma demonstrated significant anti-tumor activity in ATRT subtypes with high blood-brain barrier penetration and a safe profile.
Lantern Pharma's research on LP-184 for pediatric brain cancer offers hope for effective, low-toxicity treatments, aiming to enhance patient outcomes.
LP-184's success in improving survival rates for pediatric brain cancer highlights a potential breakthrough in cancer treatment with promising implications.
Found this article helpful?
Share it with your network and spread the knowledge!
Pharmaceutical research firm Lantern Pharma has reported promising preclinical results for LP-184, a potential breakthrough treatment for atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive form of pediatric brain cancer.
Presented by Dr. Eric Raabe of Johns Hopkins at the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference, the research revealed dramatic improvements in survival rates across mouse models. In one model, median survival increased by 345%, extending from 20 to 89 days, with statistical significance (p<0.0001).
The experimental drug demonstrated potent anti-tumor activity across ATRT subtypes, with notable characteristics including high blood-brain barrier penetration and a favorable safety profile. ATRT, driven by SMARCB1 gene inactivation, currently lacks effective low-toxicity treatments, making this research potentially transformative for pediatric oncology.
Lantern Pharma plans to launch a pediatric Phase I clinical trial in late 2025 or early 2026, following the completion of its ongoing adult trial and pending consortium approvals. This timeline represents a critical step in potentially developing a targeted therapy for a cancer with historically poor treatment outcomes.
The research underscores the potential of AI-driven drug discovery, with Lantern Pharma leveraging its machine learning platform RADR® to accelerate oncology drug development. The company's approach has enabled rapid progression from initial insights to clinical trials, typically within 2-3 years and at a relatively low cost.
Curated from InvestorBrandNetwork (IBN)
